New combo tackles tough pancreatic cancer
NCT ID NCT05052723
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatment. The goal was to see if the combination could slow cancer growth. The study is complete, and results may help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib and pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced pancreatic cancer that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drugs can cause side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536, United States